Krystal Biotech Inc (NAS:KRYS)

$ 156.01 -6.82 (-4.19%) Market Cap: 4.46 Bil Enterprise Value: 4.12 Bil PE Ratio: 82.98 PB Ratio: 5.57 GF Score: 36/100

Q1 2024 Krystal Biotech Inc Earnings Call Transcript
May 06, 2024

$156.94 (-2.58%)

Earnings
Q4 2023 Krystal Biotech Inc Earnings Call Transcript
Feb 26, 2024

$157 (+41.02%)

Earnings
Q3 2023 Krystal Biotech Inc Earnings Call Transcript
Nov 06, 2023

$103.77 (-15.05%)

Earnings
Krystal Biotech Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Krystal Biotech Inc Research & Development Oncology Program Announcement Call Transcript
Jul 27, 2023
Krystal Biotech Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Krystal Biotech Inc at William Blair Growth Stock Conference Transcript
Jun 06, 2023
Krystal Biotech Inc FDA Approval Call Transcript
May 19, 2023
Krystal Biotech Inc, Affyimmune Therapeutics Inc, Rocket Pharmaceuticals Inc and Iovance Biotherapeutics Inc at Endpoints Webinar on Moving CGTx Clinical Development- Panel Transcript
Mar 02, 2023
Krystal Biotech Inc at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022
Krystal Biotech Inc and Jeune Aesthetics Inc PEARL-1 Extension Cohort Results and the KB301 Clinical Development Program - Corporate Call Transcript
Nov 17, 2022
Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Krystal Biotech Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Krystal Biotech Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022
Krystal Biotech Inc AAD GEM-3 Phase 3 Data Corporate Call Transcript
Mar 28, 2022
Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript
Mar 22, 2022
Krystal Biotech Inc GEM-3 Phase 3 Topline Data Update Call Transcript
Nov 29, 2021
Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Krystal Biotech Inc Annual Shareholders Meeting Transcript
May 21, 2021
Krystal Biotech Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Krystal Biotech Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Krystal Biotech Inc Annual Shareholders Meeting Transcript
May 29, 2020
Krystal Biotech Inc Phase 1/2 Clinical Trial of KB103 Final Update Call Transcript
Oct 29, 2019

Krystal Biotech Inc FDA Approval Call Transcript

May 19, 2023 / 10:00PM GMT

Release Date Price: $96.06 (+9.85%)

Transcript

Operator

Thank you for standing by, and welcome to the Krystal Biotech VYJUVEK FDA Approval Conference Call. As a reminder, today's call is being recorded. I would now like to hand the conference over to your host, Meg Dodge, Head of Investor Relations and Corporate Communications. Please begin.

Meg Dodge

Krystal Biotech, Inc. - VP of IR & Corporate Communications

Hello, and thank you for joining us today to discuss the FDA approval of VYJUVEK as the first and only treatment in the U.S. for Dystrophic Epidermolysis Bullosa or DEB. With me on the call are Chairman and CEO, Krish Krishnan; Co-Founder and President of Research and Development, Suma Krishnan; Chief Commercial Officer, Andrew Orth; and Kate Romano, Chief Accounting Officer.

As we begin, I would like to point out that we'll be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.